$VREX

Should Value Investors Buy VAREX IMAGING (VREX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 20, 2025, 2:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 21, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Should Value Investors Buy VAREX IMAGING (VREX) Stock? — source image
Decision brief

The 30-second read

$VREXBullishLow
01

Why it matters

The article emphasizes value investing principles, suggesting VREX is undervalued or overlooked, potentially offering investment opportunities.

02

Market read

The article's focus on VREX's valuation and investment potential indicates moderate relevance for traders and investors interested in the medical imaging sector.

03

What to watch

Potential risks include sector volatility, macroeconomic factors affecting manufacturing and healthcare equipment markets, and company-specific risks not discussed in the article.

Timing: Moderate; the article is recent but does not specify immediate catalysts.

Background

VREX operates in the medical imaging sector, which has seen steady demand and technological advancements.

Company-level read

Ticker impact

$VREXBullishMedium confidence
Context

The article discusses VAREX IMAGING (VREX) with a bullish sentiment score of 0.42, indicating moderate positive outlook.

Expected impact

Moderate upward price movement expected over the short to medium term.

Evidence & confidence

The bullish sentiment and focus on value investing suggest potential for price appreciation, but limited technical data and the article's general nature constrain confidence.

Market effects

The article's focus on manufacturing and financial markets suggests potential positive sentiment in related sectors, but no significant sector-wide movements are indicated.

Limited; no specific regional effects are discussed.

Minimal; the article pertains primarily to US-based VREX and does not indicate global market shifts.

Counterpoint

Some analysts may view the positive sentiment as overoptimistic, citing lack of strong technical signals or recent profit-taking.

Key entities

  • VAREX IMAGING

    A manufacturer of medical imaging equipment.

  • Zacks Equity Research

    Provider of stock analysis and investment research.

Related articles

$METAMed

Futures Erase Overnight Gains As Oil Hits One-Week High, Yen Slides

US equity futures largely gave back overnight gains after oil hit a one-week high and the yen weakened. Traders await US CPI and PPI, with rate-hike bets cooling after Friday’s jobs report. JPMorgan raised its S&P 500 year-end target to 8000. Corporate movers include AAON (+8%), ABCL (+22%), HZO halted on a $53 buyout, and VREX surging on Teledyne’s $18.90 offer.

$TDYHighAI 9/10

Teledyne to acquire Varex Imaging in $1.1 billion deal

Teledyne Technologies agreed to acquire Varex Imaging in an all-cash deal valued at about $1.1 billion, paying $18.90 per share, according to the companies. The transaction would bring Teledyne’s sensing-systems business together with Varex’s medical imaging components.

$VREXHighAI 10/10

Why is Varex Imaging stock rocketing today?

Investing.com reports Varex Imaging (VREX) shares rose about 49.5% in pre-open to $18.55 after Teledyne Technologies announced an agreement to buy all outstanding Varex shares for $18.90 per share in cash, valuing the deal at about $1.1 billion including equity awards and net debt. Boards approved; close expected early 2027 pending approvals.

$XOMMed

ExxonMobil in Mozambique awards McDermott LoI for Rovuma LNG project

ExxonMobil Moçambique Limitada, for the Area 4 partners, awarded McDermott Energy Solutions a letter of intent for limited engineering and procurement supporting Rovuma LNG Phase 1 midstream development. The Area 4 partners target a final investment decision in 2026. Rovuma LNG is expected to produce 18.6 million tonnes per year, start in 2031, and ExxonMobil says it is its largest single investment.